HUTCHMED-和黄医药：Fruquintinib’s overseas sales beat

2 Aug 2024 CMB International Global Markets | Equity Research | Company Update Hutchmed (13 HK) Fruquintinib's overseas sales beat HCM's oncology/immunology product revenue reached US $128mn in 1H24 (+59.6% YoY), including US$ 43mn revenue recognised from fruquintinib's sales outside China. The consolidated revenue from oncology/immunology including R&D services and Takeda collaboration revenue, reached US $169mn in 1H24, representing 48% of the midpoint of the FY24 guidance range of US$ 300-400mn. In 2Q24, fru ...